Intravenous Fosfomycin: An Assessment of Its Potential for Use in the Treatment of Systemic Infections in Canada

Table 5

Comparative clinical studies describing outcomes for patients receiving prophylaxis with intravenous fosfomycin in combination with a second antimicrobial agent.

Trial design (reference); Operation type	Treatment regimens and outcomes
Multicenter, double-blind, randomized [57]; Elective colorectal surgery	Group 1: 259 patients received fosfomycin (8 g IV)-metronidazole before operation and second infusion of fosfomycin (8 g IV) 8 h later; Abdominal infection in 12/259 (4.6%) of patients; pneumonia in 13/259 patients (5.0%); Group 2: 258 patients received doxycyline-metronidazole before operation and second identical infusion 8 h later; Abdominal infection in 19/258 (7.4%) of patients; pneumonia in 5/258 patients (2.0%)
Prospective double-blind randomized [58]; Elective colorectal surgery	Group 1: 72 patients, 3 days before operation received placebo, 1 h before operation received fosfomycin-metronidazole (8 g IV); Infective complications in 9/72 (12.5%) of patients; Group 2: 77 patients, 2 days before operation received bacitracin-neomycin, 1 day before operation received metronidazole, 1 h before operation received ampicillin; Infective complications in 8/77 (10.4%) of patients